Reuters logo
BRIEF-Cleveland Biolabs announces commencement of in Vivo Biocomparability study
April 17, 2017 / 12:00 PM / 7 months ago

BRIEF-Cleveland Biolabs announces commencement of in Vivo Biocomparability study

April 17 (Reuters) - Cleveland Biolabs Inc

* Cleveland Biolabs announces commencement of in Vivo biocomparability study

* FDA provided CBLI with its consent for initiation of an in Vivo Biocomparability study of the formulations in non-human primates

* Planned biocomparability study is funded in part by department of defense joint Warfighter Medical Research Program contract

* FDA completed its review of a side-by-side analytical comparison of two formulations of entolimod Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below